KIDS - OrthoPediatrics Corp Stock Price, Fair Value and News

32.07USD+0.28 (+0.88%)Delayed

Market Summary

USD32.07+0.28

Delayed

0.88%

KIDS Alerts

Big jump in Revenue (Y/Y)

Losses in recent quarter

KIDS Stock Price

View Fullscreen

KIDS RSI Chart

KIDS Valuation

Market Cap

764.2M

Price/Earnings (Trailing)

-34.78

Price/Sales (Trailing)

4.72

EV/EBITDA

-118.2

Price/Free Cashflow

-16.73

KIDS Price/Sales (Trailing)

KIDS Profitability

Operating Margin

84.36%

EBT Margin

-15.00%

Return on Equity

-5.93%

Return on Assets

-5.03%

Free Cashflow Yield

-5.98%

KIDS Fundamentals

KIDS Revenue

Revenue (TTM)

161.8M

Rev. Growth (Yr)

41.46%

Rev. Growth (Qtr)

18.8%

KIDS Earnings

Earnings (TTM)

-22.0M

Earnings Growth (Yr)

-14.68%

Earnings Growth (Qtr)

-16.65%

Breaking Down KIDS Revenue

Last 7 days

3.2%

Last 30 days

7.3%

Last 90 days

8.9%

Trailing 12 Months

-29.3%

How does KIDS drawdown profile look like?

KIDS Financial Health

Current Ratio

4.45

Debt/Equity

0.03

Debt/Cashflow

-2.69

KIDS Investor Care

Shares Dilution (1Y)

2.15%

Diluted EPS (TTM)

-0.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	161.8M	0	0	0
2023	130.5M	137.1M	142.1M	148.7M
2022	100.0M	106.2M	116.1M	122.3M
2021	76.2M	89.3M	92.2M	98.0M
2020	74.3M	69.6M	71.1M	71.1M
2019	60.1M	63.2M	68.2M	72.6M
2018	48.0M	51.2M	54.7M	57.6M
2017	39.0M	41.1M	43.4M	45.6M
2016	32.6M	34.2M	35.7M	37.3M
2015	0	0	0	31.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of OrthoPediatrics Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	throdahl mark c	sold	-67,126	27.59	-2,433	-
Mar 11, 2024	bailey david r	sold	-88,646	27.59	-3,213	president and ceo
Mar 11, 2024	gerritzen daniel j	sold	-75,624	27.59	-2,741	general counsel and secretary
Mar 11, 2024	hite fred	sold	-88,150	27.59	-3,195	coo and cfo
Mar 11, 2024	odle gregory a	sold	-76,369	27.59	-2,768	president of scoliosis
Feb 22, 2024	hauser joseph w	sold	-81,458	28.06	-2,903	pres. trauma & def. correction
Dec 21, 2023	bailey david r	gifted	-	-	-1,200	president and ceo
Aug 11, 2023	schlotterback terry d	sold	-99,832	38.25	-2,610	-
Aug 07, 2023	schlotterback terry d	acquired	20,749	30.97	670	-
Aug 07, 2023	schlotterback terry d	sold (taxes)	-20,994	39.6865	-529	-

Which funds bought or sold KIDS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	AWM Investment Company, Inc.	added	14.57	382,096	14,219,000	1.86%
May 16, 2024	COMERICA BANK	reduced	-3.41	-382	2,479	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.09	-82,992	475,075	-%
May 16, 2024	JANE STREET GROUP, LLC	added	2.17	-38,220	419,000	-%
May 15, 2024	D. E. Shaw & Co., Inc.	new	-	668,580	668,580	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	added	60.77	579,368	1,889,980	0.14%
May 15, 2024	UBS ASSET MANAGEMENT AMERICAS INC	sold off	-100	-220,255	-	-%
May 15, 2024	AMERIPRISE FINANCIAL INC	reduced	-6.69	-110,293	566,142	-%
May 15, 2024	Man Group plc	sold off	-100	-260,340	-	-%
May 15, 2024	First Light Asset Management, LLC	sold off	-100	-9,672,020	-	-%

Are Funds Buying or Selling KIDS?

Are funds buying KIDS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KIDS

No. of Funds

Unveiling OrthoPediatrics Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 08, 2024	blackrock inc.	4.9%	1,166,349	SC 13G/A
Feb 14, 2024	brown capital management llc	14.21%	3,318,217	SC 13G/A
Feb 09, 2024	brown advisory inc	6.9%	1,621,102	SC 13G/A
Jan 31, 2024	blackrock inc.	5.1%	1,200,135	SC 13G
Feb 14, 2023	brown capital management llc	13.87%	3,175,993	SC 13G/A
Feb 09, 2023	brown advisory inc	6.9%	1,583,702	SC 13G/A
Feb 08, 2023	riverbridge partners llc	4.63%	941,004	SC 13G/A
Sep 22, 2022	squadron capital llc	30.1%	6,901,764	SC 13D/A
Aug 17, 2022	squadron capital llc	30.1%	6,901,764	SC 13D/A
Feb 24, 2022	blackrock inc.	4.7%	937,416	SC 13G/A

Recent SEC filings of OrthoPediatrics Corp

View All Filings

Date Filed	Form Type	Document
May 08, 2024	8-K	Current Report
May 08, 2024	SC 13G/A	Major Ownership Report
May 07, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
Apr 19, 2024	EFFECT	EFFECT
Apr 17, 2024	CORRESP	CORRESP
Apr 08, 2024	DEF 14A	DEF 14A
Apr 08, 2024	DEFA14A	DEFA14A
Mar 22, 2024	UPLOAD	UPLOAD
Mar 15, 2024	S-3	S-3

Peers (Alternatives to OrthoPediatrics Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.1M	3.7M	-71.13%	32.26%	-0.09	0.29	5.77%	8.23%

OrthoPediatrics Corp News

Latest updates

OrthoPediatrics Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	18.8%	44,685,000	37,613,000	39,972,000	39,559,000	31,588,000	30,994,000	34,950,000	32,928,000	23,417,000	24,813,000	25,079,000	26,695,000	21,462,000	18,924,000	22,205,000	13,593,000	16,356,000	18,952,000	20,744,000	18,200,000	14,656,000
Gross Profit	20.4%	32,174,000	26,714,000	30,953,000	30,025,000	23,561,000	21,224,000	25,889,000	24,981,000	18,566,000	18,081,000	18,554,000	20,443,000	16,325,000	15,118,000	17,639,000	10,061,000	12,213,000	14,450,000	15,895,000	13,619,000	10,655,000
Operating Expenses	20.5%	41,897,000	34,780,000	35,461,000	35,611,000	32,152,000	29,533,000	32,850,000	28,724,000	24,952,000	23,642,000	22,198,000	23,289,000	22,298,000	27,861,000	20,137,000	17,078,000	16,710,000	17,481,000	17,434,000	15,409,000	13,372,000
S&GA Expenses	13.9%	14,169,000	12,439,000	13,582,000	13,165,000	12,216,000	10,945,000	11,919,000	12,431,000	9,758,000	9,986,000	9,862,000	10,876,000	8,949,000	9,433,000	9,237,000	5,620,000	7,564,000	8,360,000	8,771,000	7,606,000	6,547,000
R&D Expenses	9.1%	2,998,000	2,747,000	2,387,000	2,792,000	2,270,000	2,034,000	2,206,000	1,747,000	2,027,000	1,608,000	1,302,000	1,325,000	1,308,000	2,050,000	1,077,000	881,000	1,265,000	1,905,000	1,396,000	1,234,000	1,213,000
EBITDA Margin	-56.6%	-0.04	-0.03	-0.05	0.07	0.08	0.06	0.12	-0.04	-0.07	-0.09	-0.26	-0.30	-	-	-	-	-	-	-	-	-
Interest Expenses	-310.2%	-637,000	303,000	-21,000	-294,000	210,000	61,500	-708,000	-1,212,000	-566,000	-396,000	-542,000	-581,000	-728,000	-624,000	-1,010,000	-1,399,000	-379,000	-1,306,000	-1,297,000	-632,000	-303,000
Income Taxes	-1093.9%	-2,531,000	-212,000	849,000	-401,000	-574,000	-48,000	-4,143,000	-439,000	-317,000	-238,000	-292,000	-286,000	-312,000	-723,000	-	-	-	-	-	-	-
Earnings Before Taxes	-49.7%	-10,336,000	-6,903,000	-3,742,000	-3,287,000	-7,380,000	-7,896,000	14,396,000	-772,000	-9,417,000	-166,000	-2,489,000	-4,042,000	-10,691,000	-14,736,000	-4,539,000	-9,447,000	-4,945,000	-4,329,000	-2,877,000	-2,459,000	-3,020,000
EBT Margin	-4.7%	-0.15	-0.14	-0.16	-0.03	-0.01	-0.03	0.03	-0.12	-0.16	-0.18	-0.35	-0.38	-	-	-	-	-	-	-	-	-
Net Income	-16.6%	-7,805,000	-6,691,000	-4,591,000	-2,886,000	-6,806,000	-7,848,000	18,539,000	-333,000	-9,100,000	72,000	-2,197,000	-3,756,000	-10,379,000	-14,013,000	-4,539,000	-9,447,000	-4,945,000	-5,429,000	-2,664,000	-2,618,000	-3,020,000
Net Income Margin	3.7%	-0.14	-0.14	-0.16	0.01	0.03	0.01	0.08	-0.11	-0.15	-0.17	-0.33	-0.37	-	-	-	-	-	-	-	-	-
Free Cashflow	-15.6%	-13,150,000	-11,379,000	-11,148,000	-9,996,000	-11,401,000	-2,818,000	-7,147,000	-13,438,000	-8,394,000	-2,870,000	-2,931,000	-10,701,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.4%	437	439	432	435	426	428	430	331	301	304	304	308	313	320	308	328	174	182	153	151	112
Current Assets	-10.1%	204	226	226	223	225	227	225	148	131	134	135	145	152	158	161	180	115	128	109	107	93.00
Cash Equivalents	-24.1%	24.00	31.00	11.00	10.00	35.00	9.00	37.00	39.00	19.00	9.00	8.00	12.00	23.00	30.00	90.00	113	54.00	72.00	20.00	22.00	53.00
Inventory	6.5%	113	106	101	91.00	85.00	78.00	74.00	67.00	64.00	58.00	55.00	56.00	55.00	53.00	52.00	49.00	44.00	38.00	35.00	33.00	28.00
Net PPE	18.7%	49.00	41.00	40.00	40.00	37.00	34.00	36.00	37.00	31.00	29.00	29.00	28.00	28.00	27.00	24.00	24.00	24.00	21.00	22.00	21.00	17.00
Goodwill	9.3%	91.00	84.00	81.00	83.00	84.00	87.00	88.00	15.00	5.00	72.00	70.00	70.00	68.00	71.00	60.00	68.00	52.00	14.00	11.00	11.00	-
Liabilities	7.9%	67.00	62.00	58.00	55.00	53.00	49.00	47.00	104	86.00	79.00	82.00	86.00	91.00	86.00	69.00	86.00	35.00	40.00	67.00	63.00	32.00
Current Liabilities	10.0%	46.00	42.00	48.00	44.00	35.00	31.00	29.00	31.00	34.00	30.00	28.00	30.00	37.00	35.00	26.00	25.00	14.00	14.00	46.00	42.00	11.00
Long Term Debt	2.5%	10.00	10.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21.00
LT Debt, Current	1.3%	0.00	0.00	-	-	-	0.00	-	-	-	-	-	-	-	0.00	-	-	-	0.00	-	-	0.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21.00
Shareholder's Equity	-1.7%	371	377	374	380	373	379	383	227	215	225	221	222	222	235	239	242	139	142	86.00	88.00	80.00
Retained Earnings	-3.9%	-205	-197	-191	-186	-183	-176	-168	-187	-187	-178	-178	-175	-172	-161	-147	-143	-133	-128	-123	-120	-118
Additional Paid-In Capital	0.5%	583	580	578	575	563	561	559	418	396	395	393	391	390	389	387	386	275	271	210	209	198
Shares Outstanding	-2.4%	23.00	23.00	23.00	23.00	23.00	23.00	21.00	20.00	19.00	19.00	19.00	19.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	445	-	-	-	472	-	-	-	695	-	-	-	594	-	-	-	349	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	11.3%	-6,690	-7,543	-8,669	-4,373	-6,461	-3,341	-6,058	-8,170	-4,197	-1,235	-937	-8,976	-1,915	-157	-3,666	-7,751	-6,956	-6,926	-429	-6,943	-3,471
Share Based Compensation	4.9%	2,799	2,668	2,368	3,456	2,113	1,701	1,682	1,770	1,526	1,672	1,440	1,415	1,316	1,484	1,259	2,495	958	707	733	692	471
Cashflow From Investing	-120.5%	-3,679	17,922	9,668	-18,223	32,310	-23,227	-103,919	-528	14,303	2,965	-3,044	-1,725	-5,607	-59,056	-1,288	-3,726	-5,623	-1,529	-1,736	-53,675	-4,982
Cashflow From Financing	-106.1%	-573	9,387	-15.00	-2,035	-36.00	-35.00	108,268	27,774	-33.00	-34.00	42.00	-32.00	30.00	-16.00	-19,679	70,957	-4,530	59,966	455	30,062	536

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KIDS Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenue	$ 44,685	$ 31,588
Cost of revenue	12,511	8,027
Gross profit	32,174	23,561
Operating expenses:
Sales and marketing	14,169	12,549
General and administrative	24,730	17,157
Research and development	2,998	2,446
Total operating expenses	41,897	32,152
Operating loss	(9,723)	(8,591)
Other expense (income):
Interest expense (income), net	637	(210)
Fair value adjustment of contingent consideration	0	(670)
Other income, net	(24)	(331)
Total other expense (income), net	613	(1,211)
Loss before income taxes	(10,336)	(7,380)
Provision for income taxes (benefit)	(2,531)	(574)
Net loss	$ (7,805)	$ (6,806)
Weighted average shares outstanding - basic (in shares)	22,820,779	22,506,024
Weighted average common stock - diluted (in shares)	22,820,779	22,506,024
Net loss per share - basic (in dollars per share)	$ (0.34)	$ (0.30)
Net loss per share - diluted (in dollars per share)	$ (0.34)	$ (0.30)

KIDS Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 21,602	$ 31,055
Restricted cash	1,962	1,972
Short-term investments	26,141	49,251
Accounts receivable - trade, net of allowances of $1,195 and $1,373, respectively	36,275	34,617
Inventories, net	112,689	105,851
Prepaid expenses and other current assets	5,056	3,750
Total current assets	203,725	226,496
Property and equipment, net	48,721	41,048
Other assets:
Amortizable intangible assets, net	70,382	69,275
Goodwill	91,481	83,699
Other intangible assets	18,792	15,287
Other non-current assets	4,084	2,940
Total other assets	184,739	171,201
Total assets	437,185	438,745
Current liabilities:
Accounts payable - trade	19,736	12,649
Accrued compensation and benefits	9,772	11,325
Current portion of long-term debt with affiliate	154	152
Current portion of acquisition installment payable	10,368	10,149
Other current liabilities	5,790	7,391
Total current liabilities	45,820	41,666
Long-term liabilities:
Acquisition installment payable, net of current portion	3,613	3,551
Deferred income taxes	5,202	5,483
Other long-term liabilities	1,815	1,112
Total long-term liabilities	20,781	20,054
Total liabilities	66,601	61,720
Stockholders' equity:
Common stock, $0.00025 par value; 50,000,000 shares authorized; 23,540,411 shares and 23,378,408 shares issued as of March 31, 2024 and December 31, 2023, respectively	6	6
Additional paid-in capital	583,086	580,287
Accumulated deficit	(205,547)	(197,742)
Accumulated other comprehensive loss	(6,961)	(5,526)
Total stockholders' equity	370,584	377,025
Total liabilities and stockholders' equity	437,185	438,745
Nonrelated Party
Long-term liabilities:
Long-term debt, net of current portion	9,579	9,297
Long-term debt with affiliate, net of current portion	9,579	9,297
Related Party
Long-term liabilities:
Long-term debt, net of current portion	572	611
Long-term debt with affiliate, net of current portion	$ 572	$ 611

About OrthoPediatrics Corp

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

CEO	Mr. David R. Bailey
WEBSITE	orthopediatrics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	203

OrthoPediatrics Corp Frequently Asked Questions

What is the ticker symbol for OrthoPediatrics Corp? What does KIDS stand for in stocks?

KIDS is the stock ticker symbol of OrthoPediatrics Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of OrthoPediatrics Corp (KIDS)?

As of Fri May 17 2024, market cap of OrthoPediatrics Corp is 764.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KIDS stock?

You can check KIDS's fair value in chart for subscribers.

What is the fair value of KIDS stock?

You can check KIDS's fair value in chart for subscribers. The fair value of OrthoPediatrics Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of OrthoPediatrics Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KIDS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is OrthoPediatrics Corp a good stock to buy?

The fair value guage provides a quick view whether KIDS is over valued or under valued. Whether OrthoPediatrics Corp is cheap or expensive depends on the assumptions which impact OrthoPediatrics Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KIDS.

What is OrthoPediatrics Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, KIDS's PE ratio (Price to Earnings) is -34.78 and Price to Sales (PS) ratio is 4.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KIDS PE ratio will change depending on the future growth rate expectations of investors.